Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.

ABSTRACT:

Objectives

To identify predictors of low disease activity and clinical remission following belimumab treatment in SLE.

Methods

SLE patients who received belimumab 10 mg/kg (N = 563) in the BLISS-52 and BLISS-76 clinical trials were surveyed. The performance of baseline factors in predicting attainment of low disease activity (defined as Lupus Low Disease Activity State) or clinical remission [defined as clinical (c)SLEDAI-2K = 0] at week 52 from treatment initiation was evaluated using logistic regression. Organ damage was assessed using the SLICC/ACR Damage Index (SDI).

Results

We demonstrated a negative impact of established organ damage on attainment of Lupus Low Disease Activity State [SDI > 0; odds ratio (OR): 0.44; 95% CI 0.22, 0.90; P = 0.024] and the primary L

SUBMITTER: Parodis I 

PROVIDER: S-EPMC6880848 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature